Drug intelligence / Profile preview

binimetinib + cisplatin + pemetrexed

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of binimetinib (a MEK inhibitor), cisplatin (a platinum-based chemotherapy agent), and pemetrexed (a folate analog). This regimen was studied in a phase 1B clinical trial for patients with KRAS-mutated non-small cell lung cancer (NSCLC). The treatment protocol involved 4 cycles of cisplatin 75 mg/m², pemetrexed 500 mg/m², and binimetinib (30 or 45 mg orally twice daily) followed by maintenance therapy with pemetrexed and binimetinib until disease progression or unacceptable toxicity.

Targets

GART (GAR transformylase)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)DNAMEK1 (Dual specificity mitogen-activated protein kinase kinase 1)DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)

Beyond the preview

Go deeper on binimetinib + cisplatin + pemetrexed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on binimetinib + cisplatin + pemetrexed.

Explore the full profile